49. Systemic lupus erythematosus Clinical trials / Disease details
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
Showing 1 to 8 of 8 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05326841 (ClinicalTrials.gov) | October 3, 2021 | 23/3/2022 | Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients . Effect of CholecalciferolSupplementation on Disease Activity and Quality of Life of Systemic Lupus E ... | Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients Effect of CholecalciferolSupplementation on Disease Activity and Quality of Life of Systemic Lupus E ... | Lupus Erythematosus, Systemic;Cholecalciferol Supplementation;Disease Activity;Quality of Life | Drug: Vitamin D3 | Dr Cipto Mangunkusumo General Hospital | NULL | Completed | 18 Years | 60 Years | Female | 60 | Phase 3 | Indonesia |
2 | NCT03155477 (ClinicalTrials.gov) | June 10, 2016 | 13/5/2017 | Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D | Effect Of Curcuma Xanthorrhiza Supplementation In Systemic Lupus Erythematosus Patients (SLE) With Hypovitamin D Which Were Given Vitamin D3 Towards Disease Activity (SLEDAI), Interleukin-6 (IL-6) And Tumor Growth Factor-ß1 (TGF-ß1) Serum Effect Of Curcuma Xanthorrhiza Supplementation In Systemic Lupus Erythematosus Patients (SLE) With H ... | SLE | Dietary Supplement: Cholecalciferol and C. Xanthorrhiza;Dietary Supplement: Cholecalciferol and placebo Dietary Supplement: Cholecalciferoland C. Xanthorrhiza;Dietary Supplement: Cholecalciferoland placeb ... | Saiful Anwar Hospital | NULL | Completed | 18 Years | 45 Years | Female | 39 | N/A | NULL |
3 | NCT01709474 (ClinicalTrials.gov) | June 2013 | 16/10/2012 | Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus | Vitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Drug: Vitamin D3 6000 IU;Drug: Vitamin D3 400 IU | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Terminated | 5 Years | 20 Years | All | 7 | Phase 2 | United States |
4 | NCT01892748 (ClinicalTrials.gov) | July 2012 | 17/6/2013 | Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. CholecalciferolSupplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus ... | Effects of Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Onset Systemic Lupus Erythematosus. Effects of CholecalciferolSupplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Ons ... | Systemic Lupus Erythematosus | Drug: Cholecalciferol;Drug: Placebo | ROSA MARIA RODRIGUES PEREIRA | NULL | Completed | 10 Years | 25 Years | Female | 60 | N/A | Brazil |
5 | NCT01911169 (ClinicalTrials.gov) | June 2011 | 22/7/2013 | Vitamin D to Improve Endothelial Function in SLE | Vitamin D Repletion to Improve Endothelial Function in Lupus Patients | Atherosclerosis;Systemic Lupus Erythematosus | Drug: Cholecalciferol | Medical University of South Carolina | NULL | Completed | 18 Years | 80 Years | All | 9 | Phase 2 | United States |
6 | NCT01413230 (ClinicalTrials.gov) | January 2010 | 24/6/2011 | Vitamin D Supplementation in Systemic Lupus Erythematosus | Evaluation of Immunologic Response After Vitamin D Supplementation in Patients With Systemic Lupus Erythematosus Evaluation of Immunologic Response After Vitamin D Supplementation in Patients With Systemic Lupus E ... | Vitamin D Deficiency | Drug: cholecalciferol | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | N/A | Both | 20 | N/A | France |
7 | NCT00710021 (ClinicalTrials.gov) | November 2008 | 1/7/2008 | Vitamin D3 in Systemic Lupus Erythematosus | Effect of Vitamin D3 on the IFN Alpha Signature in Patients With Systemic Lupus Erythematosus (ALE02) Effect of Vitamin D3on the IFN Alpha Signature in Patients With Systemic Lupus Erythematosus (ALE02) ... | Systemic Lupus Erythematosus;SLE;Lupus | Drug: Vitamin D3;Drug: Vitamin D3 placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Completed | 18 Years | N/A | All | 57 | Phase 2 | United States |
8 | NCT00418587 (ClinicalTrials.gov) | December 2006 | 4/1/2007 | Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE) | Phase 1 Study of Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Drug: Cholecalciferol | Medical University of South Carolina | American College of Rheumatology Research and Education Foundation;National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) American College of Rheumatology Research and Education Foundation;National Institute of Arthritis a ... | Completed | 18 Years | 85 Years | All | 18 | Phase 1 | United States |